Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
admission, burdensome, constitute, de, documentation, earlier, inclusive, joint, principle, protracted, reached, reimbursement, Settlement, stay, stockholder
Removed:
allegedly, attorney, award, range, stage, sustained, unable
Financial report summary
?Competition
AthenexManagement Discussion
- All of our research and development expense incurred through March 22, 2021 had been incurred in connection with the development of tesetaxel and since then includes the wind-down of tesetaxel-related operations. Research and development expense includes non-personnel-related and personnel-related expense. Non-personnel-related expense primarily consists of expense incurred prior to the discontinuation of development of tesetaxel and includes expense related to: (i) clinical study site payments; (ii) manufacturing development, including manufacturing registration and validation batches of tesetaxel; (iii) acquiring clinical study materials and the clinical study supply chain; (iv) clinical and quality systems; and (v) pharmacokinetic studies. Personnel-related expense includes expense related to salaries, bonuses and benefits, restructuring expense and equity-based compensation for personnel engaged in research and development functions. We expect our research and development expense to be de minimis in the near term due to the discontinuation of development of tesetaxel and wind-down of tesetaxel-related operations.